Catalyst is designed to stimulate the formation of healthy bone tissue in spinal fusions and is made of a proprietary nanocrystalline structure that’s reabsorbed and replaced by new tissue, according to a news release. A study in Biomedical Journal of Scientific & Technical Research found Catalyst had a 93% spinal fusion rate and improvements in quality of life and pain after surgery.
The bone graft was launched in August 2021 and reached 1,000 patients in May 2023.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
